Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBT: 2013-2025

Historic EBT for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Sep 2025 value amounting to $21.5 million.

  • Amphastar Pharmaceuticals' EBT fell 54.88% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $141.1 million, marking a year-over-year decrease of 28.64%. This contributed to the annual value of $195.2 million for FY2024, which is 7.29% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' EBT stood at $21.5 million, which was down 45.31% from $39.3 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' EBT peaked at $63.6 million during Q3 2023, and registered a low of $5.1 million during Q1 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median EBT value was $47.7 million (recorded in 2024), while the average stood at $42.6 million.
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' EBT spiked by 1,045.28% in 2021, and later crashed by 54.88% in 2025.
  • Amphastar Pharmaceuticals' EBT (Quarterly) stood at $27.2 million in 2021, then skyrocketed by 93.00% to $52.4 million in 2022, then decreased by 0.98% to $51.9 million in 2023, then declined by 4.88% to $49.4 million in 2024, then crashed by 54.88% to $21.5 million in 2025.
  • Its EBT stands at $21.5 million for Q3 2025, versus $39.3 million for Q2 2025 and $30.9 million for Q1 2025.